COMPANION DIAGNOSTIC BIOMARKERS OF EGFR INHIBITOR

摘要

The present invention relates to a system that verifies results predicted by genetic biomarker labeling scan (GBLscan), which is a new learning model that can reliably predict drug sensitivity by analyzing a combination of gene mutation and expression information, and a molecular profile of a drug, and to a biomarker discovered through verification. The present invention mainly consists of: a verification system that verifies through an experiment whether the expression level of a specific gene predicted by GBLscan affects drug sensitivity; and a biomarker discovered through verification. Overexpression of the LEPRE1 gene in hematological cancer cell lines shows high reactivity to Peletinib, which is an EGFR TK inhibitor, and LEPRE1 expression-inhibited cells become resistant to Peletinib. In addition, for this verification, constructed is a verification system that is expected to be used for other biomarker candidates in the future, such as an expression inhibition experiment using siRNA and Western blot, an overexpression and expression inhibition experiment using electroporation, and the like.